Related Experiment Video
Updated: Sep 27, 2025

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Is Colchicine a New Game-Changer in Patients With Acute Coronary Syndrome?
Abdul Q Nawabi1, Warda Hassan2, Lijuan Chen1
1Cardiology, Zhongda Hospital Southeast University, Nanjing, CHN.
Abstract:
Colchicine, an anti-inflammatory drug, was declared as a potently cheap and effective drug in treating atherosclerosis. This report is a detailed understanding and an in-depth interpretation of the colchicine cardiovascular outcomes trial (COLCOT) that has taken place in recent years. It is a secondary quantitative study that has reviewed studies discussing the role of colchicine in myocardial infarction, inflammation, ST-elevation myocardial infarction, and in general, acute coronary syndrome (ACS). Different trials statistically proved colchicine's role in ACS by lowering the levels of high c-reactive protein, decreasing low attenuation plaque volume, and stabilizing plaque. Hence, in other words, it has been revealed that this drug has potential in the management of ACS. Colchicine reported promising results in reducing the risk of recurrent myocardial infarction, stroke, and sudden cardiac arrest, playing a massive role in lowering inflammation and the mortality caused by cardiovascular diseases.
More Related Videos
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Drugs that Destabilize Microtubules
Drugs for Treatment of Ulcerative Colitis in IBD
Acute Coronary Syndrome I: Introduction
Coronary Artery Disease V: Interprofessional Care
Pericarditis III: Medical Management

